Clinical trials: CLDN18.2 Positive, active
Advanced Solid Tumor
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.
- Trial name
- NCT06446388
- Testing
- QLS31905, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma
IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
This study is a Phase II trial evaluating the safety and efficacy of IBI343 in combination with chemotherapy as neoadjuvant therapy for subjects with borderline resectable pancreatic cancer (BRPC).
- Trial name
- NCT07415525
- Testing
- IBI343
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Gastric or Gastroesophageal Junction Adenocarcinoma
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase II Study Evaluating the Efficacy and Safety of LM-302 in Combination with Candonilimab and Capecitabine for First-Line Treatment in Patients with Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric…
- Trial name
- NCT06587425
- Testing
- LM-302+Candonilimab+Capecitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.
This is a multicenter, randomized, controlled, open-label, Phase III study, designed to evaluate the efficacy and safety of JS107 versus investigator-selected therapy in the second-line or later treatment of patients with…
- Trial name
- NCT07284134
- Testing
- JS107 for Injection, Irinotecan, Paclitaxel
- Where
- 68 sites in China
- Volunteers
- 560 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
CLDN18.2-positive Advanced Biliary Tract Cancer
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
This is an open-label, multicenter Phase II clinical study aimed at evaluating the efficacy, safety, PK profile, and immunogenicity of QLS31905 for Injection combined with Chemotherapy ± QL2107 in Patients with CLDN18.2-positive…
- Trial name
- NCT07151872
- Testing
- QLS31905 for Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection
- Volunteers
- 120 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Gastric or Esophagogastric Junction Adenocarcinoma
Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma
In this study, the investigators will use Tislelizumab combined with LM-302 and S-1 versus Tislelizumab combined with SOX to treat Claudin 18.2-positive locally advanced gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT07569068
- Testing
- Tislelizumab, LM-302 and S-1, Tislelizumab combined with oxaliplatin and S-1
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Ruijin Hospital
Claudin 18.2, Solid Tumor Malignancies
A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors
This open-label, multicenter Phase I/II trial evaluates the combination of FG-M108 and FG-B901 in patients with unresectable locally advanced or metastatic solid tumors that are positive for Claudin 18.2 and have progressed on…
- Trial name
- NCT07704866
- Testing
- FG-B901, FG-M108
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Adenocarcinoma
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
This study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or…
- Trial name
- NCT07385703
- Testing
- LM-302 Injection, Tislelizumab, Oxaliplatin Injection
- Where
- 106 sites in China
- Volunteers
- 752 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- LUCERNA (NCT06901531)
- Testing
- zolbetuximab, Pembrolizumab, Capecitabine
- Where
- 253 sites in United States, Australia and 20 more
- Volunteers
- 500 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumor
Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors
Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer.
- Trial name
- NCT06084286
- Testing
- Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sichuan University
Gastric Cancer Adenocarcinoma Metastatic, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer
This study examines whether adding the drug Zolbetuximab to an existing treatment (Paclitaxel and Ramucirumab) can improve patients' survival.
- Trial name
- RAINSPOT (NCT06962137)
- Testing
- zolbetuximab, Retrospective cohort, no intervention
- Where
- 6 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Advanced Gastric and Pancreatic Cancer
Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer
The goal of this clinical trial is to learn if CBG131 works to treat advanced gastric cancer or pancreatic cancer in adults whose tumors are CLDN18.2-positive.
- Trial name
- NCT07394205
- Testing
- CBG131 CAR-T Cell Infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer
Zolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor.
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT03816163
- Testing
- zolbetuximab, nab-paclitaxel, gemcitabine
- Where
- 136 sites in United States, Australia and 11 more
- Volunteers
- 393 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric or Gastroesophageal Junction Adenocarcinoma
QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ
This study is a randomized, open, multicenter phase III clinical study designed to compare the efficacy and safety of QLS31905 injection combined with CAPOX versus sintilimab combined with CAPOX in the first-line treatment of…
- Trial name
- NCT07716449
- Testing
- QLS31905, Sintilimab, Oxaliplatin
- Where
- China
- Volunteers
- 560 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Cancer, Chemotherapy Effect
Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer
The goal of this clinical trial is to evaluate the efficacy and safety of LM-302 combined with gemcitabine as a second-line treatment for CLDN 18.2-positive unresectable locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT07108504
- Testing
- Gemcitabine, LM-302
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Biliary Tract Cancer
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
This is a multicenter, Phase 2 clinical trial to evaluate the efficacy and safety, PK and immunogenicity of SHR-A1904 in patients with advanced or metastatic biliary tract cancer (BTC).
- Trial name
- NCT07450976
- Testing
- SHR-A1904 for Injection
- Where
- 2 sites in China
- Volunteers
- 151 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor
A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
In Phase I, This study will explore the tolerability and safety of RC118 in patients with locally advanced unresectable or metastatic malignant solid tumors with positive Claudin 18.2 expression, and determine the maximum…
- Trial name
- NCT05205850
- Testing
- RC118-ADC
- Where
- 2 sites in China
- Volunteers
- 135 people
- Sponsor
- RemeGen Co., Ltd.
CLDN18.2 Positive, Primary Gastric Adenocarcinoma
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a prospective, randomized, open, multicenter phase II clinical trial. It plans to enroll 70 participants with locally advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC) who are assessed as…
- Conditions
- CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07483567
- Testing
- IBI343,sintilimab,oxaliplatin,S-1, sintilimab,oxaliplatin,S-1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Metastatic Solid Tumor
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
TAC01-CLDN18.2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes Claudin 18.2.
- Trial name
- TACTIC-3 (NCT05862324)
- Testing
- TAC01-CLDN18.2
- Where
- 9 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Triumvira Immunologics, Inc.
CLDN18.2-positive Advanced Solid Tumor
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
This study consists of two research phases: Phase Ib (includes dose escalation stage and efficacy expansion stage): To explore the safety, tolerability and initial efficacy of SHR-A1904 in the treatment of CLDN18.2-positive…
- Trial name
- NCT06350006
- Testing
- SHR-A1904; Adebrelimab, SHR-A1904; CAPOX; Adebrelimab
- Where
- China
- Volunteers
- 924 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.